{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:25:11Z","timestamp":1787739911685,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ejca.2011.05.007","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T02:37:33Z","timestamp":1308623853000},"page":"2117-2127","source":"Crossref","is-referenced-by-count":443,"title":["Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct00494299","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Masatoshi","family":"Kudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Chida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nakachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadatoshi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iku","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Meinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiwamu","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.05.007_b0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1440-1746.2009.06207.x","article-title":"The 2008 Okuda lecture management of hepatocellular carcinoma: from surveillance to molecular targeted therapy","volume":"25","author":"Kudo","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2011.05.007_b0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1440-1746.2009.05784.x","article-title":"Hepatocellular carcinoma in the Asia-Pacific region","volume":"24","author":"Yuen","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2011.05.007_b0015","doi-asserted-by":"crossref","unstructured":"Asia-Pacific working party on prevention of hepatocellular carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010;25:657\u201363.","DOI":"10.1111\/j.1440-1746.2009.06167.x"},{"key":"10.1016\/j.ejca.2011.05.007_b0020","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2011.05.007_b0025","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3748\/wjg.v12.i5.828","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan","volume":"12","author":"Makuuchi","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2011.05.007_b0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2011.05.007_b0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00004836-200105000-00005","article-title":"Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?","volume":"32","author":"Trevisani","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ejca.2011.05.007_b0040","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized control trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2011.05.007_b0045","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2011.05.007_b0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2011.05.007_b0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ejca.2011.05.007_b0060","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.3748\/wjg.v11.i23.3644","article-title":"The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma","volume":"11","author":"Cheng","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2011.05.007_b0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00535-005-1566-3","article-title":"Updated treatment approach to hepatocellular carcinoma","volume":"40","author":"Llovet","year":"2005","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ejca.2011.05.007_b0070","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.3748\/wjg.v16.i27.3437","article-title":"Transcatheter arterial embolizaiton with a fine-powder formulation of cisplatin for hepatocellular carcinoma","volume":"16","author":"Kasai","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2011.05.007_b0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00270-010-9975-y","article-title":"Transcatheter arterial embolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience","volume":"34","author":"Seki","year":"2011","journal-title":"Cardiovasc Intervent"},{"key":"10.1016\/j.ejca.2011.05.007_b0080","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","article-title":"Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients","volume":"131","author":"Takayasu","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2011.05.007_b0085","doi-asserted-by":"crossref","unstructured":"Groupe d\u2019Etude et de Traitement du Carcinome H\u00e9patocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256\u201361.","DOI":"10.1056\/NEJM199505113321903"},{"key":"10.1016\/j.ejca.2011.05.007_b0090","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fern\u00e1ndez","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2011.05.007_b0095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/02841850801958890","article-title":"Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization","volume":"49","author":"Wang","year":"2008","journal-title":"Acta Radiol"},{"key":"10.1016\/j.ejca.2011.05.007_b0100","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3748\/wjg.v10.i19.2878","article-title":"Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2011.05.007_b0105","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2174\/1381612023393026","article-title":"BAY 43-9006: preclinical data","volume":"8","author":"Wilhelm","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejca.2011.05.007_b0110","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.05.007_b0115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2011.05.007_b0120","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.05.007_b0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2011.05.007_b0130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2957\/kanzo.45.380","article-title":"Criteria for the evaluation of direct efficacy in treatment of liver cancer","volume":"45","author":"Liver Cancer Study Group of Japan","year":"2004","journal-title":"Kanzo"},{"key":"10.1016\/j.ejca.2011.05.007_b0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2214\/ajr.175.3.1750699","article-title":"Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma","volume":"175","author":"Takayasu","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ejca.2011.05.007_b0140","first-page":"81","article-title":"Hepatic artery embolization in 32 patients with unresectable hepatoma","volume":"26","author":"Yamada","year":"1980","journal-title":"Osaka City Med J"},{"key":"10.1016\/j.ejca.2011.05.007_b0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","article-title":"Hepatic artery embolization in 120 patients with unresectable hepatoma","volume":"148","author":"Yamada","year":"1983","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2011.05.007_b0150","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1349-7006.2008.00909.x","article-title":"Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients","volume":"99","author":"Shim","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2011.05.007_b0155","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjc.6605017","article-title":"Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis","volume":"100","author":"Schoenleber","year":"2009","journal-title":"Br J Cancer"},{"issue":"15 Suppl.","key":"10.1016\/j.ejca.2011.05.007_b0180","article-title":"Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE)","volume":"28","author":"Lencioni","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.05.007_b0165","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2010.28.7805","article-title":"Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.05.007_b0170","unstructured":"Park J-W, Kim HY, Shim JH, et al. Interim analysis of a phase II study of the combination of TACE and sorafenib for unresectable hepatocellular carcinoma in National Cancer Center Korea (COTSUN Korea Trial). In: Proceedings of the fourth annual conference of the International Liver Cancer Association (ILCA), Montreal, Queb\u00e9c, Canada; 10\u201312 September 2010. p. 26 [Abstract O-027]."},{"key":"10.1016\/j.ejca.2011.05.007_b0175","unstructured":"US national institutes of health. Transcatheter arterial chemoembolization therapy in combination with sorafenib (TACTICS), NCT01217034. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01217034?term=sorafenib\u00b1AND\u00b1tactics&rank=1 [accessed 07.12.10]."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911003248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911003248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T21:00:13Z","timestamp":1712523613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911003248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0959804911003248"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.05.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}